Metropolitan Life Insurance CO Forma Therapeutics Holdings, Inc. Transaction History

Metropolitan Life Insurance CO

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Jun 14, 2023	BUY	$7.12 - $20.24 $15,720 - $44,689	2,208 New	2,208 $44.1 Million
Q2 2022 Jun 20, 2023	BUY	$5.1 - $10.0 $11,260 - $22,080	2,208 New	2,208 $15,000
Q1 2022 Jun 20, 2023	BUY	$8.34 - $14.69 $18,414 - $32,435	2,208 New	2,208 $20,000
Q1 2022 Mar 30, 2023	SELL	$8.34 - $14.69 $58,263 - $102,624	-6,986 Reduced 75.98%	2,208 $20,000
Q1 2022 May 12, 2022	SELL	$8.34 - $14.69 $58,263 - $102,624	-6,986 Reduced 75.98%	2,208 $21,000
Q4 2021 Jun 21, 2023	BUY	$13.6 - $24.89 $125,038 - $228,838	9,194 New	9,194 $130,000
Q3 2021 Jun 21, 2023	BUY	$21.22 - $25.7 $195,096 - $236,285	9,194 New	9,194 $213,000
Q2 2021 Jun 21, 2023	BUY	$22.86 - $30.95 $210,174 - $284,554	9,194 New	9,194 $228,000
Q2 2021 Mar 30, 2023	BUY	$22.86 - $30.95 $10,629 - $14,391	465 Added 5.33%	9,194 $228,000
Q2 2021 Aug 16, 2021	BUY	$22.86 - $30.95 $209,969 - $284,275	9,185 Added 102055.56%	9,194 $229,000
Q1 2021 Jun 26, 2023	BUY	$24.58 - $42.82 $214,558 - $373,775	8,729 New	8,729 $245 Million
Q1 2021 Mar 30, 2023	BUY	$24.58 - $42.82 $95,862 - $166,998	3,900 Added 80.76%	8,729 $244,000
Q1 2021 May 14, 2021	SELL	$24.58 - $42.82 $118,475 - $206,392	-4,820 Reduced 99.81%	9 $245,000
Q4 2020 Jun 22, 2023	BUY	$34.9 - $51.08 $168,532 - $246,665	4,829 New	4,829 $168,000
Q3 2020 Jun 26, 2023	BUY	$32.95 - $50.25 $159,115 - $242,657	4,829 New	4,829 $240,000
Q3 2020 Mar 30, 2023	BUY	$32.95 - $50.25 $159,115 - $242,657	4,829 New	4,829 $240,000
Q3 2020 Nov 13, 2020	BUY	$32.95 - $50.25 $159,115 - $242,657	4,829 New	4,829 $241,000

26.5K

Ticker FMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,860,400
Market Cap $958M
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.